Sign In
Buy TBPH
$16.90
-0.0300 (-0.177%)
At Close: Jul 13, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
03:00pm, Thursday, 09'th Jul 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK PR Newswire
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
08:30am, Wednesday, 01'st Jul 2026
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yup
Theravance Stock Down 3% After Zymeworks Announces Buyout
09:55am, Tuesday, 30'th Jun 2026
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
02:00pm, Monday, 29'th Jun 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) PR Newswir
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
02:00pm, Monday, 29'th Jun 2026
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 29, 2026
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
01:59pm, Monday, 29'th Jun 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
01:36pm, Monday, 29'th Jun 2026
NEW YORK, June 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and i
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh en
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
11:00am, Monday, 29'th Jun 2026
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
10:02am, Monday, 29'th Jun 2026
MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced tr
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
09:20am, Monday, 29'th Jun 2026
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
Zymeworks strikes $929 million deal for Theravance Biopharma
06:13am, Monday, 29'th Jun 2026
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
02:30pm, Friday, 08'th May 2026
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
10:50am, Thursday, 07'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
